While CHIP was initially recognized as a premalignant condition [21, 22] with an increased risk of hematologic malignancies, it has since been implicated in non-hematologic diseases, particularly cardiovascular diseases, through its promotion of chronic inflammation and vascular dysfunction [14, 17, 18]. Here, STUB1 is linked to hematologic disorder.